JNJ Stock Recent News
JNJ LATEST HEADLINES
Jared Holz, Mizuho, joins 'Fast Money' to talk what to expect from the upcoming slate of health care earnings.
Johnson & Johnson (JNJ) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Johnson & Johnson stock (NYSE: JNJ) will report its Q1 2024 results on Tuesday, April 16. We expect the company to post revenue of $21.5 billion and earnings of $2.68, compared to the consensus estimates of $21.4 billion and $2.64, respectively.
Pharmaceuticals firm Johnson & Johnson kicks off earnings season for the sector on Tuesday. Investors want executives to put to rest ongoing talc litigation.
Blue Chip stocks to watch in the stock market today.
Rwanda's drug regulator has recalled a batch of Johnson & Johnson children's cough syrup as a precautionary measure after its Nigerian counterpart said laboratory tests found high levels of toxicity.
South Africa's health regulator said on Saturday it is recalling batches of Johnson & Johnson's children's cough syrup after detection of high levels of diethylene glycol.
J&J's (JNJ) Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Stelara. Surgical procedure recovery and new products are likely to have driven MedTech sales.
Johnson & Johnson: Doubling Down On This 2024 Dog Of The Dow
Johnson & Johnson (NYSE:JNJ) will report first quarter results next Tuesday, 16 April, hot on the heels of its acquisition of Shockwave Medical. This US$13.1 billion deal saw J&J move further into the cardiovascular intervention market, under wider plans to enter “higher growth” sectors, the pharmaceutical giant said at the time.